🚨Trade Alert 🚨 OKYO

🚨Trade Alert 🚨 OKYO͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ Wall Street may soon have its eye on Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO), an emerging company developing first-in-class pharmaceutical therapies to treat inflammatory eye diseases. This ophthalmology-focused bio-pharma company is developing its game-changing OK-101 drug candidate to treat dry eye disease (DED) – a condition that addresses a significant unmet need in a multi-billion-dollar market! Now may be a critical time to have the company on your radar as only weeks ago, the U.S. Food and Drug Administration (FDA) cleared OKYO’s Investigational New Drug (IND) to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED! [](~/AASl5QA~/RgRl0gAHP0RjaHR0cHM6Ly9va3lvcGhhcm1hLmNvbS8_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlB3vvY0crgoBSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~) Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) is a quietly trading biopharma company that is at the early stages of its growth story. THE TOP 10 REASONS TO HAVE OKYO ON YOUR RADAR: - OKYO’s immediate goal is to overcome the limitations of current dry eye treatments with the development of a first-in-class drug that combines both anti-inflammatory and ocular pain-reducing activity typically unaffected by. - Dry eye patients suffer from corneal neuropathic pain, making their condition resistant to anti-inflammatory drugs. - Worldwide, [700 million patients](~/AASl5QA~/RgRl0gAHP0SBaHR0cHM6Ly9va3lvcGhhcm1hLmNvbS9kaXNlYXNlLWZvY3VzL2RyeS1leWUtZGlzZWFzZS8_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlB3vvY0crgoBSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~) suffer from dry eye disease. In the United States, 20 million patients suffer from dry eye disease. - Currently, there is NO FDA approved topical treatment for ocular pain. - OKYO’s drug candidate OK-101 has potential to capture a big piece of the eye disease market. - In an animal model, OKYO’s lead drug candidate OK-101 was effective in suppressing ocular inflammation by downregulating key inflammatory CD4+ T cells. Additional studies are ongoing to determine the efficacy of OK-101 in diminishing ocular redness, the most common symptom of allergic conjunctivitis. - The company has received FDA clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of dry eye disease (DED). - OKYO has patent protection until 2039! - The company has an experienced team with considerable drug development expertise. - Last year Non-Executive Chairman Gabriele Marco Cerrone bought over 6M shares on the LSE at a price per share of UK£0.061. Executives and board members are more confident about the direction of their company when they start buying up more shares. Greetings Investors, The healthcare arena is just what the doctor ordered for 2023 as inflation continues and a recession looms. Healthcare is one of the most stable industries, and people will continue to spend money on medicine regardless of how the economy is doing. Additionally, the [World Health Organization (WHO)](~/AASl5QA~/RgRl0gAHP0SOaHR0cHM6Ly93d3cud2hvLmludC9uZXdzLXJvb20vZmFjdC1zaGVldHMvZGV0YWlsL2FnZWluZy1hbmQtaGVhbHRoP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZjUXA4THRRLXk1WEkzdmlZbDV1d2NON3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5Qd772NHK4KAUht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAF4bE~) has estimated that the number of people who are aged 60 and older will almost double by 2050, The market will reach a staggering 426 million people. What does this mean? It means more prescription drugs will keep older people healthy and active as their bodies wear down. As baby boomers age, eye issues continue to boom. As more people spend their time on screens, eye issues continue to accelerate. The growing eye industry is something investors can’t ignore much longer. Of your five senses, eyesight ranks at the top. And when eyes are affected by various conditions, people will do what they can to alleviate their symptoms and improve their eye condition. Dry eye disease is one of the most common ocular eye conditions. It’s no surprise that the market has become extensive for dry eye drugs including brand names like Novartis’ Xiidra and Allergan’s Restasis. These drugs are expensive too. Xiidra is not usually covered by Medicare insurance plans and there is no generic alternative available for Xiidra. Restasis is a prescription eye drop that increases tear production to relieve chronic dry eye and can also cost hundreds of dollars. Not to mention that both drugs come with side effects, have inadequate efficacy, and a slow onset of action. This is why OKYO is a Massive Opportunity “We are very pleased to receive clearance from the FDA to initiate our OK-101 Phase 2 study. We believe this first-in-human study will help demonstrate that OK-101 may provide a new way to treat DED patients who are not well-served by currently approved drugs. Based on earlier feedback from the FDA we are designating primary and secondary efficacy endpoints in this study that include both a sign and a symptom of the disease. Should our Phase 2 study meet its prespecified primary endpoint, it may accelerate the timeline to a new drug application (NDA) filing for OK-101 with the FDA. The clearance of our IND for OK-101 has been a key priority for the company this past year, and we are excited to be moving this drug into the clinic in the first quarter of 2023.”- Gary S. Jacob, Ph.D., Chief Executive Officer Healthcare research for the eyes is laying the groundwork for drug technology that has never been seen before and treatments and therapies are becoming more sophisticated with every passing year. Being conscious of which companies are successful in capitalizing on innovative ways to treat eye problems could be advantageous for any portfolio! What makes OKYO stand out in the neuropathic eye treatment space is a new chemical entity that targets BOTH inflammation and ocular pain in dry eye disease! Something that has yet to be done! Such a solution opens a wide door for OKYO to tap into an underserved niche market and creates the potential for shareholder growth. Company Overview OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a life sciences company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor (GPCR), which the company believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. The company’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. OKYO is concentrating on the development of its drug candidate OK-101 to treat ocular diseases, including: - Dry eye disease (DED) huveitis - Allergic conjunctivitis - Ocular pain The immediate focus of the company is the clinical development of OK-101 to treat dry eye disease (DED). In November 2022 the company filed an IND to treat DED with the U.S. Food and Drug Administration, which is soon to be followed by the planned commencement of a Phase 2 trial in DED patients in the first quarter of 2023. This is around the corner! OKYO also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis, and allergic conjunctivitis. OKYO CEO Gary Jacob has told Proactive’s Andrew Scott it’s time to take the company from the development stage and into the clinic. Link to video: [ The Bottom Line This is one of the most exciting times for Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) as they move toward initiating a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED. Novel therapies such as the potential drug OK-101, that improve the signs and symptoms of dry eye disease, will be beneficial to dry eye patients and those suffering from ocular pain. Start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in OKYO. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party Open Market Media Group for a One Day Marketing Program regarding OKYO with a start date of 2/17/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](~/AASl5QA~/RgRl0gAHP0SoaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDRURDdWWFhaQlBQQ0o4WTNSS1FCOCZrPTM5YzgyMGVlMjY3Y2RjYjM0YjQxMWVmMGM1NmY1MWE5Jm09MDFHU0VQRTJOMko4MUFWM0NSRDdWVFQzVjgmcj1XYmJBRVNaVwNzcGNCCmPlB3vvY0crgoBSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~). Small Caps Daily 1334 Northampton St Easton, PA 18042